PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology

Federica Miglietta; Michela Cinquini; Maria Vittoria Dieci; Laura Cortesi; Carmen Criscitiello; Filippo Montemurro; Lucia Del Mastro; Alberto Zambelli; Laura Biganzoli; Alessia Levaggi; Chiara Delle Piane; Caterina Marchiò; Massimo Calabrese; Lucio Fortunato; Pierfrancesco Franco; Bruno Meduri; Veronica Andrea Fittipaldo; Stefania Gori

doi:10.1016/j.breast.2022.10.014

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The Panel of AIOM BC Clinical Practice Guideline provided clinical recommendations on the use of PARP-inhibitors, with respect to single-agent chemotherapy, in patients with BRCA-related HER2-advanced BC by adopting the GRADE methodology.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Miglietta et al. (2022) studied this question.

synapsesocial.com/papers/69d6f506e328128020aa890b https://doi.org/10.1016/j.breast.2022.10.014

View Full Paper

Ask AI

Bookmark

Share

PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology

Ask about this paper

Abstract

Discussion

Cite This Study

PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading